Want to join the conversation?
$MRK said that it's planning to submit a supplemental Biologics License Application (sBLA) to the U.S. FDA for KEYTRUDA (pembrolizumab) by the end of 2015 based on the findings from KEYNOTE-010 clinical trial. The company is also intending to submit a Marketing Authorization Application to the European Medicines Agency in early 2016.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?